Cargando…
Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease with a broad spectrum of disease severity. HCM ranges from a benign course to a progressive disorder characterized by angina, heart failure, malignant arrhythmia, syncope, or sudden cardiac death. So far,...
Autores principales: | Tafelmeier, Maria, Baessler, Andrea, Wagner, Stefan, Unsoeld, Bernhard, Preveden, Andrej, Barlocco, Fausto, Tomberli, Alessia, Popovic, Dejana, Brennan, Paul, MacGowan, Guy A., Ristic, Arsen, Velicki, Lazar, Olivotto, Iacopo, Jakovljevic, Djordje G., Maier, Lars S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244301/ https://www.ncbi.nlm.nih.gov/pubmed/32125709 http://dx.doi.org/10.1002/clc.23346 |
Ejemplares similares
-
Gender Related Differences in the Clinical Presentation of Hypertrophic Cardiomyopathy—An Analysis from the SILICOFCM Database
por: Preveden, Andrej, et al.
Publicado: (2022) -
Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy
por: Velicki, Lazar, et al.
Publicado: (2020) -
Haemodynamic determinants of quality of life in chronic heart failure
por: Fatrin, Serlie, et al.
Publicado: (2022) -
Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial
por: Tajstra, Mateusz, et al.
Publicado: (2023) -
Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
por: Jaffuel, Dany, et al.
Publicado: (2018)